ALKS · XBRL financial data

Alkermes financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ALKS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,039	1,174	1,112	1,663	1,558	1,476
Cost of goods and services sold	178	197	218	253	245	196
Research and development	395	407	394	271	245	324
Selling, general and administrative	539	561	606	690	645	702
General and administrative	—	—	199	200	199	222
Operating income (loss)	(112)	(29)	(142)	414	421	254
Interest income	7	2	8	31	42	45
Interest expense	9	11	13	23	23	12
Other income (expense)	14	0	2	(0)	3	4
Income tax expense (benefit)	14	9	(9)	(98)	72	50
Net income (loss)	(111)	(48)	(158)	356	367	242
Earnings per share, basic USD per share	(0.70)	(0.30)	(0.97)	2.14	2.22	1.47
Earnings per share, diluted USD per share	(0.70)	(0.29)	(0.97)	2.10	2.17	1.43
Weighted average shares, basic millions of shares	159	161	164	166	165	165
Weighted average shares, diluted millions of shares	159	165	164	170	169	169

Fiscal years (ALKS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	273	338	292	457	291	389
Short-term investments	362	199	—	—	—	—
Marketable securities	362	199	316	316	461	200
Marketable securities, non-current	—	228	130	38	73	—
Inventory	126	150	181	186	183	197
Prepaid and other current assets	61	49	44	98	91	79
Total current assets	1,111	1,062	1,130	1,486	1,415	1,929
Property and equipment, net	350	341	325	227	228	222
Right-of-use asset	132	116	116	91	84	77
Goodwill	93	93	93	83	83	83
Total assets	1,950	2,024	1,964	2,136	2,056	2,487
Accounts payable	46	56	33	66	46	108
Current portion of long-term debt	3	3	3	3	—	0
Total current liabilities	438	471	498	520	465	543
Long-term debt	272	293	290	288	—	0
Lease liability, non-current	119	104	90	76	69	63
Total liabilities	883	912	920	934	591	668
Accumulated deficit	(1,493)	(1,541)	(1,699)	(1,344)	(976)	(735)
Total stockholders' equity	1,067	1,113	1,044	1,203	1,465	1,819
Total liabilities and equity	1,950	2,024	1,964	2,136	2,056	2,487
Common shares outstanding (cover page) millions of shares	159	162	164	167	163	167

Fiscal years (ALKS's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(111)	(48)	(158)	356	367	242
Stock-based compensation	90	88	94	101	97	99
Depreciation and amortization	82	79	78	75	29	27
Net cash from operating activities	83	102	21	401	439	521
Purchases of property and equipment	42	28	38	48	33	40
Net cash from investing activities	(11)	(66)	(65)	53	(111)	295
Share repurchases	—	—	—	—	200	—
Proceeds from long-term debt	—	24	—	—	—	—
Repayments of long-term debt	3	2	3	3	2	—
Net cash from financing activities	(2)	29	(2)	(290)	(494)	12
Net change in cash	69	65	(45)	165	(166)	829

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Ionis Pharmaceuticals	350	268	566*	166.2M	—	Q2 FY26 10-QJun 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Madrigal Pharmaceuticals	515	431	121*	23.2M	—	Q3 FY26 10-QSep 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.